Role of remdisivir among COVID-19 patient’s recovery.
DOI:
https://doi.org/10.29309/TPMJ/2021.28.12.6787Keywords:
Corona Virus Disease, Hospital Stay, Oxygen Support Category, Remedisvir, Severe Acute Respiratory Syndrome, World Health OrganizationAbstract
Objective: To assess the effect of Remedisvir, its safety Profile, and efficacy among COVID-19 patients. Study Design: Retrospective Observational study. Setting: South East Hospital and Research Center, Islamabad, Pakistan. Period: December 2020 to July 2021. Material & Methods: 100 patients were included in this study who received Remedisvir infusion, day 5, 7, and 10 after admitting the hospital with COVID-19 symptoms. We infuse 200mg I/V Remedisvir in 100cc N/S followed by 100mg I/V daily into 100cc N/S. After infusion, all patients were monitored strictly. Results: The mean age of the patients was (51. 89±15.441). The outcome of Remedisvir showed that 14% improved their condition, 42% discharged with oxygen, 27% discharged without oxygen, and only 17% expired). Remedisvir showed a positive effect at (p≤0.001) among laboratory values and oxygen support category. Conclusion: When patient suffering from COVID-19 symptoms and low oxygen saturation show good clinical outcome treated with Remedisvir. According to the results of our study, it is concluded that, at present Remedisvir remains a good drug, it shows a positive effect on oxygen saturation and length of hospital stay.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 The Professional Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.